

# Jerome A Zack

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/232716/publications.pdf>

Version: 2024-02-01

73  
papers

8,921  
citations

81900

39  
h-index

74163

75  
g-index

76  
all docs

76  
docs citations

76  
times ranked

8883  
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. <i>Cell</i> , 1990, 61, 213-222.	28.9	1,657
2	Negative Regulation of Neural Stem/Progenitor Cell Proliferation by the <i>Pten</i> Tumor Suppressor Gene in Vivo. <i>Science</i> , 2001, 294, 2186-2189.	12.6	761
3	HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. <i>Nature</i> , 1990, 348, 69-73.	27.8	703
4	Interferon-Inducible Cholesterol-25-Hydroxylase Broadly Inhibits Viral Entry by Production of 25-Hydroxycholesterol. <i>Immunity</i> , 2013, 38, 92-105.	14.3	554
5	The CCR5 and CXCR4 Coreceptors are Central to Understanding the Transmission and Pathogenesis of Human Immunodeficiency Virus Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 111-126.	1.1	441
6	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	30.7	395
7	The SCID-hu mouse as a model for HIV-1 infection. <i>Nature</i> , 1993, 363, 732-736.	27.8	327
8	A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. <i>Cell Stem Cell</i> , 2016, 18, 533-540.	11.1	307
9	Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. <i>Nature Medicine</i> , 2009, 15, 285-292.	30.7	259
10	Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency. <i>Journal of Virology</i> , 2002, 76, 8118-8123.	3.4	205
11	Molecular Characterization, Reactivation, and Depletion of Latent HIV. <i>Immunity</i> , 2003, 19, 413-423.	14.3	184
12	Interleukin-7 Induces Expression of Latent Human Immunodeficiency Virus Type 1 with Minimal Effects on T-Cell Phenotype. <i>Journal of Virology</i> , 2002, 76, 13077-13082.	3.4	170
13	Generation of HIV latency during thymopoiesis. <i>Nature Medicine</i> , 2001, 7, 459-464.	30.7	165
14	Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. <i>Nature Chemistry</i> , 2012, 4, 705-710.	13.6	152
15	A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. <i>Blood</i> , 2010, 115, 1534-1544.	1.4	132
16	Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11698-11703.	7.1	130
17	HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. <i>Molecular Therapy</i> , 2015, 23, 1358-1367.	8.2	111
18	HIV Latency in the Humanized BLT Mouse. <i>Journal of Virology</i> , 2012, 86, 339-347.	3.4	106

#	ARTICLE	IF	CITATIONS
19	Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. <i>Immunology</i> , 2001, 103, 270-280.	4.4	100
20	Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12955-12960.	7.1	97
21	Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. <i>PLoS Pathogens</i> , 2017, 13, e1006753.	4.7	91
22	Medial HOXA genes demarcate haematopoietic stem cell fate during human development. <i>Nature Cell Biology</i> , 2016, 18, 595-606.	10.3	81
23	HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2016, 90, 6999-7006.	3.4	80
24	Activation of Latent HIV Using Drug-Loaded Nanoparticles. <i>PLoS ONE</i> , 2011, 6, e18270.	2.5	80
25	Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. <i>Nature Medicine</i> , 1997, 3, 1102-1109.	30.7	75
26	In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells. <i>PLoS Pathogens</i> , 2012, 8, e1002649.	4.7	74
27	In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. <i>PLoS Pathogens</i> , 2017, 13, e1006575.	4.7	73
28	Lymphoid Regeneration from Gene-Corrected SCID-X1 Subject-Derived iPSCs. <i>Cell Stem Cell</i> , 2015, 16, 367-372.	11.1	68
29	Human Immunodeficiency Virus Inhibits Multilineage Hematopoiesis In Vivo. <i>Journal of Virology</i> , 1998, 72, 5121-5127.	3.4	67
30	Humanized Mouse Models for Human Immunodeficiency Virus Infection. <i>Annual Review of Virology</i> , 2017, 4, 393-412.	6.7	65
31	CD4 Ligation on Human Blood Monocytes Triggers Macrophage Differentiation and Enhances HIV Infection. <i>Journal of Virology</i> , 2014, 88, 9934-9946.	3.4	63
32	Human Immunodeficiency Virus Type 1-Induced Hematopoietic Inhibition Is Independent of Productive Infection of Progenitor Cells In Vivo. <i>Journal of Virology</i> , 1999, 73, 9089-9097.	3.4	60
33	Regions of Human Immunodeficiency Virus Type 1 <i>nef</i> Required for Function In Vivo. <i>Journal of Virology</i> , 1998, 72, 7032-7039.	3.4	56
34	Eradication of HIV: current challenges and new directions. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 7-10.	3.0	55
35	Bioengineered Vaults: Self-Assembling Protein Shell Lipophilic Core Nanoparticles for Drug Delivery. <i>ACS Nano</i> , 2014, 8, 7723-7732.	14.6	54
36	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. <i>Cell Stem Cell</i> , 2019, 25, 542-557.e9.	11.1	48

#	ARTICLE	IF	CITATIONS
37	HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. <i>Blood</i> , 2013, 122, 2195-2204.	1.4	47
38	HIV restriction in quiescent CD4+T cells. <i>Retrovirology</i> , 2013, 10, 37.	2.0	45
39	HIV/AIDS eradication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4003-4010.	2.2	40
40	Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy. <i>Stem Cells and Development</i> , 2016, 25, 1863-1873.	2.1	37
41	Introduction of Exogenous T-cell Receptors Into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-cell Receptor Expression. <i>Molecular Therapy</i> , 2013, 21, 1055-1063.	8.2	36
42	Latency reversal plus natural killer cells diminish HIV reservoir in vivo. <i>Nature Communications</i> , 2022, 13, 121.	12.8	36
43	Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 10688-10698.	7.1	34
44	Prostratin and Bortezomib are Novel Inducers of Latent Kaposi'S Sarcoma-Associated Herpesvirus. <i>Antiviral Therapy</i> , 2005, 10, 745-751.	1.0	34
45	Studies of retroviral infection in humanized mice. <i>Virology</i> , 2015, 479-480, 297-309.	2.4	33
46	Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. <i>Virology</i> , 2018, 520, 83-93.	2.4	33
47	Effect of Latent Human Immunodeficiency Virus Infection on Cell Surface Phenotype. <i>Journal of Virology</i> , 2002, 76, 1673-1681.	3.4	31
48	Primary Cell Model for Activation-Inducible Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2007, 81, 7424-7434.	3.4	31
49	Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy. <i>Nature Communications</i> , 2020, 11, 1879.	12.8	29
50	Rapid Expression of Human Immunodeficiency Virus following Activation of Latently Infected Cells. <i>Journal of Virology</i> , 2006, 80, 1599-1603.	3.4	28
51	RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e227.	5.1	28
52	Human Immunodeficiency Virus Bearing a Disrupted Central DNA Flap Is Pathogenic In Vivo. <i>Journal of Virology</i> , 2007, 81, 6146-6150.	3.4	26
53	Establishment and maintenance of HIV latency: model systems and opportunities for intervention. <i>Future Virology</i> , 2010, 5, 97-109.	1.8	26
54	Pharmacological Activation of Non-canonical NF- $\kappa$ B Signaling Activates Latent HIV-1 Reservoirs In Vivo. <i>Cell Reports Medicine</i> , 2020, 1, 100037.	6.5	26

#	ARTICLE	IF	CITATIONS
55	Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1 <sup>+</sup> and TIGIT <sup>+</sup> CD4 T Cells. <i>Journal of Virology</i> , 2019, 93, .	3.4	21
56	Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques. <i>JCI Insight</i> , 2021, 6, .	5.0	19
57	Robust CAR-T memory formation and function via hematopoietic stem cell delivery. <i>PLoS Pathogens</i> , 2021, 17, e1009404.	4.7	19
58	Disruption of Type I Interferon Induction by HIV Infection of T Cells. <i>PLoS ONE</i> , 2015, 10, e0137951.	2.5	18
59	Cocaine-mediated impact on HIV infection in humanized BLT mice. <i>Scientific Reports</i> , 2015, 5, 10010.	3.3	16
60	Experimental Approaches for Eliminating Latent HIV. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2015, 6, 91-99.	0.1	16
61	Double Trouble: HIV Latency and CTL Escape. <i>Cell Host and Microbe</i> , 2015, 17, 141-142.	11.0	15
62	Essential Role of Human T Cell Leukemia Virus Type 1 <i>orf-I</i> in Lethal Proliferation of CD4 <sup>+</sup> Cells in Humanized Mice. <i>Journal of Virology</i> , 2019, 93, .	3.4	15
63	HIV Type 1 Infection Alters Cytokine mRNA Expression in Thymus. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1-12.	1.1	14
64	Engineering HIV-Specific Immunity with Chimeric Antigen Receptors. <i>AIDS Patient Care and STDs</i> , 2016, 30, 556-561.	2.5	14
65	New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. <i>Translational Research</i> , 2017, 187, 83-92.	5.0	13
66	Functional Reconstitution of Thymopoiesis after Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2000, 74, 2943-2948.	3.4	12
67	Neutralizing the HIV Reservoir. <i>Cell</i> , 2014, 158, 971-972.	28.9	12
68	Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	12
69	Preparation and Maintenance of SCID-hu Mice for HIV Research. <i>Methods</i> , 1997, 12, 343-347.	3.8	11
70	HIV cure strategies: a complex approach for a complicated viral reservoir?. <i>Future Virology</i> , 2019, 14, 5-8.	1.8	11
71	Tracking HIV Rebound following Latency Reversal Using Barcoded HIV. <i>Cell Reports Medicine</i> , 2020, 1, 100162.	6.5	11
72	HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. <i>Virology</i> , 2011, 417, 394-399.	2.4	8

#	ARTICLE	IF	CITATIONS
73	Cocaine exposure impairs multilineage hematopoiesis of human hematopoietic progenitor cells mediated by the sigma-1 receptor. Scientific Reports, 2015, 5, 8670.	3.3	5